Taiwanese health authorities are investigating a possible link between blindness and GLP-1 drugs, like the popular weight-loss drug Ozempic. A doctor in Taipei reported that a man suffered an “eye stroke” after injecting a GLP-1 class drug for 10 months. The patient reportedly went completely blind in one eye and lost almost all vision in the other. The case comes as the US Food and Drug Administration has recently warned of a similar potential complication. In Taiwan, GLP-1 drugs are currently approved only for the treatment of type 2 diabetes, not for weight loss. According to Taiwan's health authorities, the nation has received 314 reports of suspected adverse reactions linked to the drugs so far, including 12 cases involving eye disorders.